Plavix

Cirrhosis, Liver

M.D. Anderson Cancer CenterPhase 2/3Active

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 55/ 100
Competitive Position: 81/ 100

Competitive context

23 Active assets in the Cirrhosis, Liver cohort.

Asset / Sponsor	Phase	Rating
Methylene Blue Institute of Liver and Biliary Sciences, India	Phase 4	BB
Ceftriaxone Shahida Islam Medical Complex	Phase 4	BB
Resmetirom Madrigal Pharmaceuticals, Inc.	Phase 3	B
Doptelet Hvidovre University Hospital	Phase 4	B
Heplisav-B Mercy Medical Center	Phase 4	B

View all 35 →

Same molecule, other indications

Plavix is also rated in:

myocardial infarctionDormant

A

Indicative ·

81 / 100

transient ischemic attackDormant

BBB

Indicative ·

77 / 100

peripheral arterial diseaseDormant

BBB

Indicative ·

77 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.